The drugmaker is reporting a shortage of two insulin aspart injection solutions while seven others remain in steady supply, according to a Nov. 10 post from the ASHP. A reason for the shortage was not provided, as available solutions are on back order and allocation.
Novo Nordisk is also discontinuing two insulin detemir solutions — Levemir Flexpen subcutaneous injection, 100 units per milliliter pen; and Levemir subcutaneous injection, 100 units per milliliter vial — in the U.S. market. The supply of pens is expected to deplete in April, and the company predicts the vials’ supply to be exhausted in December 2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
